Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Profound Medical Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5595)
•••
Post by retiredcfon May 20, 2021 7:01am
113 Views
Post# 33236163

Top Gainers

Top GainersCould use more trading volume but we'll take it. GLTA

Symbol/ Company Price $ Change $ Volume
Data delayed at least 15 minutes, as of 19/05/2021 4:00 PM ET | All market data delayed
WDO
Wesdome Gold Mines Ltd
 $11.40 CAD +$1.67(17.11%) 1.68M
THNC
Thinkific Labs Inc
 $14.10 CAD (8.76%) 53.28K
GCL
Colabor Group Inc
 $1.08 CAD (8.00%) 52.55K
LPEN
Loop Energy Inc
 $9.07 CAD (7.46%) 8.97K
EGLX
Enthusiast Gaming Holdings Inc
 $7.62 CAD (7.32%) 473.38K
TLG
Troilus Gold Corp
 $1.22 CAD (7.02%) 1.58M
GRID
Tantalus Systems Holding Inc
 $2.70 CAD (5.88%) 28.10K
PRN
Profound Medical Corp
 $22.27 CAD (5.55%) 18.67K

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities